D 21266 (perifosine)

11/01/2014 - "A phase I and pharmacokinetic study of oral perifosine with different loading schedules in patients with refractory neoplasms."
12/01/2011 - "In the current study, the effect of perifosine, an Akt inhibitor, on the chemosensitivity of TrkB-expressing NB cells or tumors was evaluated. "
06/02/2010 - "Our study supports the future clinical evaluation of perifosine for the treatment of NB tumors."
11/15/2007 - "Perifosine is a member of the class of synthetic alkylphospholipids (APLs) and is being evaluated as anti-cancer agent in several clinical trials. "
07/01/2007 - "The Akt inhibitor, perifosine, is an alkylphospholipid exhibiting antitumor properties and is currently in phase II clinical trials for various types of cancer. "

10/01/2013 - "The evidence from clinical trials supporting the use of perifosine in the therapy of leukemias is limited. "
10/01/2013 - "Perifosine has the potential to play a role in the treatment of leukemias in the future. "
10/01/2013 - "In preclinical leukemia models, perifosine has an independent cytotoxic potential but also synergizes well with other rationally selected targeted agents. "
01/01/2008 - "Perifosine was tested on THP-1 and MV 4-11 cell lines, as well as primary leukemia cells. "
03/15/2005 - "Together, these findings indicate that coadministration of HDACIs with perifosine in human leukemia cells leads to Akt and MEK/ERK disruption, a marked increase in ceramide and ROS production, and a striking increase in mitochondrial injury and apoptosis. "

07/01/2006 - "In addition, perifosine, an inhibitor of Akt activation that exhibits substantial antimyeloma activity in preclinical models, is being examined in relapsed multiple myeloma. "
05/15/2006 - "Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells."
07/01/2007 - "Perifosine is a novel alkyl-lysophospholipid that can induce apoptosis in multiple myeloma (MM) tumor cells, both in vitro and in vivo. "
04/01/2010 - "Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma."
05/15/2006 - "Here we show that baseline phosphorylation of Akt in multiple myeloma (MM) cells is completely inhibited by perifosine [octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate] in a time- and dose-dependent fashion, without inhibiting phosphoinositide-dependent protein kinase 1 phosphorylation. "

12/01/2012 - "Our study shows that coadministration of curcumin and an orally bioactive alkylphospholipid perifosine results in a significant increase in colorectal cancer cell apoptosis and a marked inhibition of cell growth both in vitro and in vivo. "
11/20/2011 - "In a multicenter, double-blind phase II trial, we compared the efficacy and safety of perifosine plus capecitabine (P-CAP) with placebo plus capecitabine (CAP) in patients with metastatic colorectal cancer (mCRC) who had progressed after as many as two prior therapies. "
11/20/2011 - "Randomized placebo-controlled phase II trial of perifosine plus capecitabine as second- or third-line therapy in patients with metastatic colorectal cancer."
12/01/2012 - "We conclude that perifosine sensitizes colorectal cancer cells to curcumin by modulating multiple signaling pathways. "
12/01/2012 - "Perifosine sensitizes curcumin-induced anti-colorectal cancer effects by targeting multiple signaling pathways both in vivo and in vitro."

10/01/2010 - "Our present studies showed that Akt phosphorylation was inhibited by perifosine in HepG2 and Bel-7402 human hepatocellular carcinoma cells. "
10/01/2010 - "In this study, the effect of perifosine on the cell proliferation and apoptosis in hepatoma cells has been investigated. "
10/01/2010 - "Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of Akt phosphorylation."
10/01/2010 - "Our findings suggest that the small molecule Akt inhibitor perifosine shows substantial anti-tumor activity in human hepatoma cancer cell lines, and is a good candidate for treatment combinations with classical cytostatic compounds in hepatocellular carcinoma."
08/01/2015 - "Efficacy of perifosine alone and in combination with sorafenib in an HrasG12V plus shp53 transgenic mouse model of hepatocellular carcinoma."